Psoriasis | Treatment Algorithms: Claims Data Analysis | Adult Psoriasis | US | 2024
The treatment of adult psoriasis represents an increasingly lucrative market for biologics for moderate to severe disease, for which conventional systemic and topical treatments are not sufficient. The dominance of well-established biologics, such as AbbVie’s TNF-α inhibitor Humira, Johnson & Johnson Innovative Medicine’s IL-12/23 inhibitor Stelara, and Novartis’s IL-17 inhibitor Cosentyx, is being challenged by newer, more-effective therapies, including Eli Lilly’s IL-17 inhibitor Taltz, AbbVie’s latest-in-class IL-23 inhibitor Skyrizi, and the latest market arrival, UCB’s IL-17 A/F dual inhibitor Bimzelx. Amgen’s PDE-4 inhibitor Otezla, the only oral targeted therapy for many years, is facing fierce competition from Bristol Myers Squibb’s Sotyktu, an oral TYK2 inhibitor approved in September 2023. The launch of multiple biosimilars of adalimumab will further affect market dynamics.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult psoriasis? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult psoriasis patients?
- How have newer biologics such as Taltz, Bimzelx, Tremfya, and Skyrizi been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of adult psoriasis patients receive drug therapy within a year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
- What percentage of adult psoriasis patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
CONTENT HIGHLIGHTS
Markets covered: United States
Key companies: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, UCB
Key drugs: Bimzelx, Cosentyx, Duobrii, Humira, Otezla, Skyrizi, Stelara, Sotyktu, Taltz, Tremfya, Vtama
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
